About Mitokinin
Mitokinin is a Healthcare company based in New York (United States) founded in 2012 by Daniel de Roulet, and was acquired by AbbVie in October 2023. PINK1-targeted kinetins for Parkinsons and cardiomyopathy are developed. Mitokinin has raised $9.53 million across 3 funding rounds from investors including AbbVie and HHS. Its chief executive, as recorded, is Daniel de Roulet. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative.
Company details
Mitokinin was founded in 2012 in New York, United States, as an early-stage biopharmaceutical company. Small molecule ATP analogs known as kinetins are developed to target PTEN-induced putative kinase 1 for mitochondria-associated disorders, including familial Parkinsons Disease and certain cardiomyopathies. Intellectual property for these analogs and their methods of use is licensed from UCSF.
- Headquarters New York, United States
- Founders Daniel de Roulet
- Stage Acquired
- SectorsHealthcare
- Website mitokinin.com
- Social LinkedIn
- Acquired by AbbVie (Oct 2023)
Funding Insights of Mitokinin
Mitokinin has successfully raised a total of $9.53M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.53M
- Total Rounds 3
- Last Round Series A — $5M
- First Round $4.53M
(Sep 2017)
- Investors Count 1
All 3 funding rounds of Mitokinin with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2018 | $5M | Series A | – | – | – |
| Sep 2018 | $225,000 | Grant | – | – | |
| Sep 2017 | $4.53M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in Mitokinin
Mitokinin has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include AbbVie and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | abbvie.com | Chicago, United States |
Investor details for Mitokinin
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mitokinin
21 people are tracked at Mitokinin (5 in leadership, 9 in board & advisors, 7 in team).
| Name | Role | Group |
|---|---|---|
Daniel de Roulet | Co-Founder & CEO | Leadership |
Nicholas Hertz | Co-founder & CSO | Leadership |
Rishi Rakhit | Director, Translation | Leadership |
Dara Ditsworth | Director, Cell Biology | Leadership |
Randall Chin | Director, Biomarkers | Leadership |
Kevan Shokat | Co-founder & Scientific Advisor | Board & advisors |
Ted Dawson | Scientific Advisor | Board & advisors |
Miratul Muqit | Scientific Advisor | Board & advisors |
Jean-Francois Trempe | Scientific Advisor | Board & advisors |
Flint Beal | Scientific Advisor | Board & advisors |
Michael D. Taylor | Executive Chairman | Board & advisors |
Peter Parker | Director | Board & advisors |
Rana Al-Hallaq | Director | Board & advisors |
Douglas Crawford | Director | Board & advisors |
Chengzhong Wang | Principal Scientist | Team |
Song Liu | Senior Scientist | Team |
Jessica Li | Research Associate | Team |
Katharina von Löhneysen, Ph.D | Research Scientist | Team |
Tou Lee | Laboratory Manager | Team |
Phwe Phwe H. | Research And Development Associate | Team |
1 more people are available in the full profile.
Complete people profiles for Mitokinin
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Mitokinin
4 dated milestones of Mitokinin across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Mitokinin is founded.
- Funding First funding round of $4.5M.
- Funding Latest funding round, Series A, of $5.0M.
- Exit Acquired by AbbVie.
Top companies in Neurology
3 companies that operate in the same segment as Mitokinin (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mitokinin
Complete news archive for Mitokinin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mitokinin
Mitokinin was founded in 2012 and raised its 1st funding round 5 years after it was founded.
Mitokinin is headquartered in New York, United States. It is registered at New York, New York, United States.
Daniel de Roulet is the CEO of Mitokinin, as recorded in our data. They have also founded this company.
Mitokinin is a funded company, having raised a total of $9.53M across 3 funding rounds to date. The company's 1st funding round was a Series A of $4.53M, raised on Sep 2017.
Mitokinin was founded in 2012 in New York, United States, as an early-stage biopharmaceutical company. Small molecule ATP analogs known as kinetins are developed to target PTEN-induced putative kinase 1 for mitochondria-associated disorders, including familial Parkinsons Disease and certain cardiomyopathies. Intellectual property for these analogs and their methods of use is licensed from UCSF.
Yes. Mitokinin was acquired by AbbVie in October 2023.